EGFR and neoplasm: Importantly, GP73 is a key driver of hypoxia influencing the TME and tumor immunity by regulating programmed death-ligand 1 (PD-L1) expression through the EGFR/STAT3 signaling pathway in HCC7 and endoplasmic reticulum stress in tumors leading to an immunosuppressive microenvironment promoting PD-L1 stabilization, transporting PD-L1 to tumor-associated macrophages (TAMS) and leading to CD+8 T-cell suppression.8